- In May 2023, GenScript Biotech Corporation expanded its principal manufacturing plant for oligonucleotide production in Jiangsu, China. This expansion aims to meet the growing demand for oligos and peptides in the APAC region, supporting advancements in biopharma, particularly in molecular diagnostics, RNAi, and gene editing. The enhanced facility is equipped with state-of-the-art facilities and automated workstations, boosting capacity to meet diverse research and IVD (In Vitro Diagnostics) kit material needs
- In December 2024, Co-Diagnostics, Inc. and CoSara Diagnostics inaugurated a new oligonucleotide synthesis facility in Ranoli, India. This initiative supports the "Make in India" program and is designed to manufacture Co-Diagnostics' patented Co-Primers® chemistry, which is crucial for their lab-based PCR diagnostic tests. This development is expected to facilitate access to India's large healthcare market and enhance manufacturing efficiency
- In October 2023, Integrated DNA Technologies (IDT) opened a new therapeutic manufacturing facility to address the growing demand in genetic medicine. While the specific location for this facility is not explicitly stated as APAC in the provided snippets, IDT has a growing presence in the Asia-Pacific region, driven by increasing demand for precision diagnostics and therapeutic oligos. This facility is designed to enable the manufacture of therapeutic oligonucleotides, meeting the growing need in genomics and personalized medicine globally, with implications for APAC's expanding market
- In May 2023, Twist Bioscience and CeGaT GmbH collaborated to develop the Twist Alliance CeGaT RNA Fusion Panel, a specific tool for oncology research aimed at detecting RNA fusions and transcript variation analysis. Such collaborations, even if initiated outside APAC, contribute to the global advancement of oligonucleotide-based research tools which are increasingly adopted in the Asia-Pacific region's growing oncology research sector
